The aim of our study was to evaluate the effect of KvLQT1 activation, with the pharmacological activator R-L3, delivered directly to the lung, on the main outcomes of bleomycin-induced ALI, during the acute exudative phase (at day 7). Here, KCNQ1 is linked to acute respiratory distress syndrome.